Co-Diagnostics (OTC:CODX) reported quarterly losses of $(1.46) per share which beat the analyst consensus estimate of $(3.00) by 51.33 percent. This is a 78.84 percent increase over losses of $(6.90) per share from the same period last year. The company reported quarterly sales of $166.131 thousand which missed the analyst consensus estimate of $166.500 thousand by 0.22 percent. This is a 1.98 percent increase over sales of $162.910 thousand the same period last year.